Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / FibroBiologics
Company

FibroBiologics

Tracked across 2 events · 17 articles · First seen Apr 10, 2026 · Last active Jun 16, 2026

Sentiment
72
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 75
Tech
FibroBiologics Thymic Organoid Preclinical Data
Impact: FibroBiologics announced preclinical data for its thymic organoid platform, which shows potential to reverse age-related immune decline and generate antigen-specific T cells with anti-tumor activity. This development could significantly enhance the company's pipeline and market position.
Apr 10, 2026 · 6 articles
4 70
Tech
FibroBiologics Doses First CYWC628 Patients
Impact: FibroBiologics is the clinical-stage biotechnology company that announced the dosing of the first patients in its Phase 1/2 clinical trial for CYWC628, a significant milestone in its development of therapeutics for diabetic foot ulcers. This event positively impacts the company's stock price and reputation.
Jun 03, 2026 · 11 articles
ERGEN INTELLIGENCE
Track FibroBiologics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.